As early as 1995, Deshane et al. [41] reported on the intraperitoneal delivery of an AdV-based vector to express an anti-human epidermal growth factor receptor 2 (HER2) scFv intrabody in mouse cancer models. This evidence concerns the gene ERBB2 and cancer.